Update shared on08 Aug 2025
Fair value Decreased 15%The decrease in Haemonetics' price target primarily reflects a significant reduction in consensus revenue growth forecasts, partially offset by improved net profit margin expectations, leading to a revised fair value of $85.18.
What's in the News
- Haemonetics Corporation (NYSE:HAE) added to Russell 2000 Dynamic Index
Valuation Changes
Summary of Valuation Changes for Haemonetics
- The Consensus Analyst Price Target has fallen from $92.45 to $85.18.
- The Consensus Revenue Growth forecasts for Haemonetics has significantly fallen from 4.0% per annum to 2.5% per annum.
- The Net Profit Margin for Haemonetics has risen from 16.88% to 18.39%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.